How is the FDA Stopping Off-Brand Ozempic?
A federal deadline ending the sale of off-brand weight-loss and diabetes medications is now in effect, cutting off access to drugs many patients count on.
The U.S. Food and Drug Administration (FDA) already declared that shortages of popular GLP-1 medications have ended, CNN reported. Those medications include semaglutide (Ozempic and Wegovy) and tirzepatide (Mounjaro and Zepbound).
That means compounded versions of these drugs made by smaller pharmacies and sold without FDA approval can no longer be legally produced or sold. The deadline for stopping production and distribution of compounded tirzepatide passed in March. Thursday was the final day for compounded semaglutide.
Excerpted from U.S. News
